Saturday 17 October 2026
Export UPB’s income statement to Excel — free account
Upstream Bio, Inc.
Upstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue fell 17.5%, EPS grew 1.35% and free cash flow grew 9.33%, each against the same quarter a year earlier.
2.76
0.61
−18.10%
Follow UPB
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 11.46 | 60.99 |
P/S ratio |
27.97 | 94.91 | 512.30 |
Altman Z″-Score (non-manufacturers) |
12.38 | 45.58 | 25.63 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | 6.55 | (2.81) |
P/Operating CF |
(4.76) | (11.47) | (47.73) |
P/B ratio |
0.00 | 0.48 | 4.30 |
Price to Tangible BV |
0.00 | 0.48 | 4.30 |
EV/Sales |
(64.82) | (103.59) | 392.64 |
EV/EBITDA |
2.44 | 3.09 | 0.00 |
EV/Operating CF |
2.77 | 4.15 | (8.41) |
EV/FCF |
2.77 | 4.10 | (8.39) |
Quick Ratio |
16.87 | 43.87 | 25.44 |
Current Ratio |
17.96 | 44.63 | 26.15 |
Net Debt/EBITDA |
2.66 | 5.93 | 2.11 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.01 | 0.01 |
Operating CF/Net income |
0.99 | 0.77 | 0.93 |
Capex/Depreciation |
0.12 | 0.33 | 0.13 |
| 0.00% | (44.07%) | (35.43%) | |
| 0.00% | (25.51%) | (34.34%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(34.58%) | (16.29%) | (42.33%) |
Average Days of Receivables |
15.03 | 94.41 | 85.43 |
Research and Development Expense of Revenue |
1,336.09% | 2,656.79% | 4,793.48% |
Selling, General and Administrative Expense of Revenue |
449.37% | 724.39% | 925.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
143.99% | 253.33% | 362.02% |
Graham Net Nets |
3.23 | 2.08 | 0.23 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(75.10%) | (38.08%) | (9.83%) |
Free Cash Flow Yield |
(83.71%) | (26.60%) | (9.14%) |
Revenue per Share |
0.81 | 0.17 | 0.05 |
Operating CF per Share |
(12.84) | (4.32) | (2.47) |
Capex per Share |
(0.05) | (0.04) | 0.00 |
Free Cash Flow per Share |
(12.89) | (4.36) | (2.48) |
Cash per Share |
37.17 | 34.38 | 6.34 |
Shareholders Equity per Share |
36.50 | 34.34 | 6.31 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
36.50 | 34.34 | 6.31 |
Free Cash Flow |
(38.07) | (59.68) | (133.44) |
Working Capital |
110.48 | 468.42 | 338.35 |
Capital Expenditures |
(0.14) | (0.51) | (0.16) |
Net Current Asset Value |
107.61 | 467.29 | 337.80 |
EV/EBIT |
2.53 | 3.16 | 0.00 |
Capex to Sales |
0.06 | 0.22 | 0.06 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
(7.55) | (2.69) | (2.35) |
Cash ROIC |
(17.49%) | (6.35%) | (19.59%) |
Accounts Receivable Turnover |
0.00 | 6.67 | 4.46 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.36 | 0.64 |
Average Payables |
— | 3.02 | 3.38 |
Average Assets |
— | 299.46 | 417.75 |
Average Common Equity |
— | 173.36 | 404.81 |
Columns are period end dates